High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer

Research output: Contribution to journalArticle

Standard

High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer. / Hjelm, Barbara; Brennan, Donal J.; Zendehrokh, Nooreldin; Eberhard, Jakob; Nodin, Björn; Gaber, Alexander; Ponten, Fredrik; Johannesson, Henrik; Smaragdi, Kristina; Frantz, Christian; Hober, Sophia; Johnson, Louis Banka; Påhlman, Sven; Jirström, Karin; Uhlen, Mathias.

In: Proteomics Clinical Applications, Vol. 5, No. 11-12, 2011, p. 624-635.

Research output: Contribution to journalArticle

Harvard

Hjelm, B, Brennan, DJ, Zendehrokh, N, Eberhard, J, Nodin, B, Gaber, A, Ponten, F, Johannesson, H, Smaragdi, K, Frantz, C, Hober, S, Johnson, LB, Påhlman, S, Jirström, K & Uhlen, M 2011, 'High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer', Proteomics Clinical Applications, vol. 5, no. 11-12, pp. 624-635. https://doi.org/10.1002/prca.201100020

APA

CBE

MLA

Vancouver

Author

Hjelm, Barbara ; Brennan, Donal J. ; Zendehrokh, Nooreldin ; Eberhard, Jakob ; Nodin, Björn ; Gaber, Alexander ; Ponten, Fredrik ; Johannesson, Henrik ; Smaragdi, Kristina ; Frantz, Christian ; Hober, Sophia ; Johnson, Louis Banka ; Påhlman, Sven ; Jirström, Karin ; Uhlen, Mathias. / High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer. In: Proteomics Clinical Applications. 2011 ; Vol. 5, No. 11-12. pp. 624-635.

RIS

TY - JOUR

T1 - High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer

AU - Hjelm, Barbara

AU - Brennan, Donal J.

AU - Zendehrokh, Nooreldin

AU - Eberhard, Jakob

AU - Nodin, Björn

AU - Gaber, Alexander

AU - Ponten, Fredrik

AU - Johannesson, Henrik

AU - Smaragdi, Kristina

AU - Frantz, Christian

AU - Hober, Sophia

AU - Johnson, Louis Banka

AU - Påhlman, Sven

AU - Jirström, Karin

AU - Uhlen, Mathias

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Create Health (000080030), Pathology, (Lund) (013030000), Division of Translational Cancer Research (013250500), Pathology (Malmö) (013031000), Surgery Research Unit (013242220)

PY - 2011

Y1 - 2011

N2 - Purpose: In this study, we investigated the prognostic impact of human RBM3 expression in colorectal cancer using tissue microarray-based immunohistochemical analysis. Experimental design: One polyclonal antibody and four monoclonal anti-RBM3 antibodies were generated and epitope mapped using two different methods. Bacterial display revealed five distinct epitopes for the polydonal antibody, while the four mouse monoclonal antibodies were found to bind to three of the five epitopes. A peptide suspension bead array assay confirmed the five epitopes of the polydonal antibody, while only one of the monoclonal antibodies could be mapped using this approach. Antibody specificity was confirmed by Western blotting and immunohistochemistry, including siRNA-mediated knock-down. Two of the antibodies (polydonal and monoclonal) were subsequently used to analyze RBM3 expression in tumor samples from two independent colorectal cancer cohorts, one consecutive cohort (n = 270) and one prospectively collected cohort of patients with cancer of the sigmoid colon (n = 305). RBM3-expression was detected, with high correlation between both antibodies (R = 0.81, p < 0.001). Results: In both cohorts, tumors with high nuclear RBM3 staining had significantly prolonged the overall survival. This was also confirmed in multivariate analysis, adjusted for established prognostic factors. Conclusion and clinical relevance: These data demonstrate that high tumor-specific nuclear expression of RBM3 is an independent predictor of good prognosis in colorectal cancer.

AB - Purpose: In this study, we investigated the prognostic impact of human RBM3 expression in colorectal cancer using tissue microarray-based immunohistochemical analysis. Experimental design: One polyclonal antibody and four monoclonal anti-RBM3 antibodies were generated and epitope mapped using two different methods. Bacterial display revealed five distinct epitopes for the polydonal antibody, while the four mouse monoclonal antibodies were found to bind to three of the five epitopes. A peptide suspension bead array assay confirmed the five epitopes of the polydonal antibody, while only one of the monoclonal antibodies could be mapped using this approach. Antibody specificity was confirmed by Western blotting and immunohistochemistry, including siRNA-mediated knock-down. Two of the antibodies (polydonal and monoclonal) were subsequently used to analyze RBM3 expression in tumor samples from two independent colorectal cancer cohorts, one consecutive cohort (n = 270) and one prospectively collected cohort of patients with cancer of the sigmoid colon (n = 305). RBM3-expression was detected, with high correlation between both antibodies (R = 0.81, p < 0.001). Results: In both cohorts, tumors with high nuclear RBM3 staining had significantly prolonged the overall survival. This was also confirmed in multivariate analysis, adjusted for established prognostic factors. Conclusion and clinical relevance: These data demonstrate that high tumor-specific nuclear expression of RBM3 is an independent predictor of good prognosis in colorectal cancer.

KW - Antibodies

KW - Colorectal cancer

KW - Epitope mapping

KW - Prognosis

KW - RNA-binding

KW - protein

U2 - 10.1002/prca.201100020

DO - 10.1002/prca.201100020

M3 - Article

VL - 5

SP - 624

EP - 635

JO - Proteomics Clinical Applications

T2 - Proteomics Clinical Applications

JF - Proteomics Clinical Applications

SN - 1862-8354

IS - 11-12

ER -